BC Innovations | Nov 12, 2015
Targets & Mechanisms

Breaking down beliefs

Researchers at the Genentech Inc. unit of Roche are challenging the widely held belief that the blood-brain barrier (BBB) breaks down in Alzheimer's disease to cause neurodegeneration and acts as a gateway for delivery of...
BC Innovations | Jan 15, 2015
Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
BC Week In Review | Sep 29, 2014
Clinical News

2B3-201: Phase I data

A double-blind, crossover, Dutch Phase I trial in 18 healthy male volunteers showed that single ascending doses of up to 450 mg 2B3-201 were well tolerated with no serious adverse events reported. Subjects received an...
BC Week In Review | Sep 15, 2014
Company News

to-BBB management update

to-BBB technologies B.V. , Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Hired: Anders Harfstrand as CEO, formerly president and CEO of Humabs BioMed S.A. ; he succeeds interim CEO Leonard Kruimer, who remains...
BC Week In Review | Jul 14, 2014
Company News

Prosensa Holding N.V management update

Prosensa Holding N.V . (NASDAQ:RNA), Leiden, the Netherlands   Business: Musculoskeletal, Neurology   Hired: Willem van Weperen as chief commercial officer, a newly created position, formerly CEO of to-BBB technologies B.V.  ...
BC Week In Review | Jul 14, 2014
Financial News

to-BBB technologies B.V completes venture financing

to-BBB technologies B.V ., Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Date completed: 2014-06-30   Type: Venture financing   Raised: EUR10 million ($13.7 million)   Investors: New investors; existing investors  ...
BC Week In Review | Jul 14, 2014
Company News

to-BBB technologies B.V management update

to-BBB technologies B.V ., Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Hired: Pericles Calias as SVP of translational medicine, formerly senior director of nonclinical development of mRNA therapy at Shire plc  ...
BC Extra | Jul 1, 2014
Financial News

to-BBB raises EUR 10M in series C

Drug delivery company to-BBB technologies B.V. (Leiden, the Netherlands) raised EUR 10 million ($13.7 million) in a series C round from new and existing investors. The company's investors include Aescap Venture; Antea Participaties; Jonghoud International;...
BC Week In Review | Jan 13, 2014
Company News

to-BBB management update

to-BBB technologies B.V. , Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Hired: Leonard Kruimer as CFO, formerly CFO of Crucell N.V. , which Johnson & Johnson acquired  ...
BC Week In Review | Dec 23, 2013
Company News

Sihuan, to-BBB deal

to-BBB partnered with Sihuan's Sun Moral International (HK) Ltd. subsidiary to use to-BBB's G-Technology drug delivery technology with undisclosed Sihuan compounds. to-BBB said the compounds cover "all diseases with CNS involvement," including neurodegenerative diseases and...
Items per page:
1 - 10 of 43
BC Innovations | Nov 12, 2015
Targets & Mechanisms

Breaking down beliefs

Researchers at the Genentech Inc. unit of Roche are challenging the widely held belief that the blood-brain barrier (BBB) breaks down in Alzheimer's disease to cause neurodegeneration and acts as a gateway for delivery of...
BC Innovations | Jan 15, 2015
Finance

Consortia cross-talk

There's no doubt that the consortium model is here to stay, but the challenge now is to avoid creating a bureaucracy of committees with duplicate missions and redundancies of effort. The answer might be a...
BC Week In Review | Sep 29, 2014
Clinical News

2B3-201: Phase I data

A double-blind, crossover, Dutch Phase I trial in 18 healthy male volunteers showed that single ascending doses of up to 450 mg 2B3-201 were well tolerated with no serious adverse events reported. Subjects received an...
BC Week In Review | Sep 15, 2014
Company News

to-BBB management update

to-BBB technologies B.V. , Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Hired: Anders Harfstrand as CEO, formerly president and CEO of Humabs BioMed S.A. ; he succeeds interim CEO Leonard Kruimer, who remains...
BC Week In Review | Jul 14, 2014
Company News

Prosensa Holding N.V management update

Prosensa Holding N.V . (NASDAQ:RNA), Leiden, the Netherlands   Business: Musculoskeletal, Neurology   Hired: Willem van Weperen as chief commercial officer, a newly created position, formerly CEO of to-BBB technologies B.V.  ...
BC Week In Review | Jul 14, 2014
Financial News

to-BBB technologies B.V completes venture financing

to-BBB technologies B.V ., Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Date completed: 2014-06-30   Type: Venture financing   Raised: EUR10 million ($13.7 million)   Investors: New investors; existing investors  ...
BC Week In Review | Jul 14, 2014
Company News

to-BBB technologies B.V management update

to-BBB technologies B.V ., Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Hired: Pericles Calias as SVP of translational medicine, formerly senior director of nonclinical development of mRNA therapy at Shire plc  ...
BC Extra | Jul 1, 2014
Financial News

to-BBB raises EUR 10M in series C

Drug delivery company to-BBB technologies B.V. (Leiden, the Netherlands) raised EUR 10 million ($13.7 million) in a series C round from new and existing investors. The company's investors include Aescap Venture; Antea Participaties; Jonghoud International;...
BC Week In Review | Jan 13, 2014
Company News

to-BBB management update

to-BBB technologies B.V. , Leiden, the Netherlands   Business: Drug delivery, Cancer, Neurology   Hired: Leonard Kruimer as CFO, formerly CFO of Crucell N.V. , which Johnson & Johnson acquired  ...
BC Week In Review | Dec 23, 2013
Company News

Sihuan, to-BBB deal

to-BBB partnered with Sihuan's Sun Moral International (HK) Ltd. subsidiary to use to-BBB's G-Technology drug delivery technology with undisclosed Sihuan compounds. to-BBB said the compounds cover "all diseases with CNS involvement," including neurodegenerative diseases and...
Items per page:
1 - 10 of 43